Evaluation of CBCT based dose calculation in the thorax and pelvis using two generic algorithms

• Published in: Physica medica 2022-11, Vol.103, p.157-165
• Main Authors: Thing, R.S., Nilsson, R., Andersson, S., Berg, M., Lund, M.D.
• Format: Article
• Language: English
• Subjects: Adaptive radiotherapy; Artefact correction; Cone beam CT; Deformable image registration
• ISSN: 1120-1797; 1724-191X
• DOI: 10.1016/j.ejmp.2022.10.012

This work examines the dosimetric performance of two algorithms creating a corrected CBCT (corrCBCT) and a virtual CT (vCT) implemented in a commercial treatment planning system. 60 patients distributed across all patient groups treated with curative intent at Vejle Hospital (breast, lung, prostate and anal/rectal cancer) were selected for the present study. Clinical treatment plans were recalculated on corrCBCT and vCT, as well as a reference CT (refCT) acquired as close in time to the CBCT image as possible. Recalculated doses were compared using gamma analysis, as well as by comparing D98%, D50%, and D2% for all delineated targets and organs at risk. High dosimetric accuracy is demonstrated on both the corrCBCT and vCT. Gamma 2%/2mm pass rates >98% were found for all patients except two outliers still having >93% pass rates. Equivalence of all evaluated dose metrics within ±1Gy was observed for all patient groups, while the pelvic patients additionally showed equivalence for all metrics within ±1% of the refCT dose. For the thoracic patients, equivalence within ±2.5% was established for all metrics except median dose to the ipsilateral lung, calculated on corrCBCT for the breast patient group. The corrCBCT and vCT images are shown in excellent dosimetric agreement with refCT images, and show high potential for future use for streamlined adaptive radiotherapy workflows. •Accurate CBCT based dose calculation is demonstrated using two different algorithms.•Both algorithms perform only post-processing and are CBCT-vendor agnostic.•Dose calculation accuracy is evaluated on 20 thoracic and 40 pelvic patients.•Gamma 2%/2 mm pass rates above 98% is shown for 58/60 patients.•Equivalence to CT-based dose within 1 Gy is shown for all evaluated dose metrics.